Mader, Julia K. http://orcid.org/0000-0001-7854-4233
Haas, Waltraud
Aberer, Felix
Boulgaropoulos, Beate
Baumann, Petra
Pandis, Marlene
Horvath, Karl
Aziz, Faisal
Köhler, Gerd
Pieber, Thomas R.
Plank, Johannes
Sourij, Harald
Article History
Received: 22 October 2018
Accepted: 8 July 2019
First Online: 17 July 2019
Competing Interests
: J. Mader is a member in the advisory board of Boehringer Ingelheim, Becton-Dickinson, Eli Lilly, Medtronic and sanofi-aventis, received speaker honoraria from Abbott Diabetes Care, Astra Zeneca, Eli Lilly, Nintamed, NovoNordisk A/S, Roche Diabetes Care, sanofi-aventis, Servier and Takeda and is shareholder of decide Clinical Software GmbH. KH received speaker honoraria from NovoNordisk A/S and Novartis. F. Aberer has received speaker honoraria from Astra Zeneca and Boehringer Ingelheim. G. Köhler is advisory board member and on speaker’s bureau of Abbott Diabetes Care, Boehringer Ingelheim, Eli Lilly, NovoNordisk and Sanofi. T. Pieber is an advisory board member of Novo Nordisk A/S, a consultant for Roche Diabetes Care, Novo Nordisk A/S, Eli Lilly & Co, Infineon, Carnegie Bank, on speaker’s bureau of Novo Nordisk A/S and Astra Zeneca and is shareholder of decide Clinical Software GmbH. H. Sourij is an advisory board member and on speaker’s bureau of Amgen, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, MSD, NovoNordisk and Sanofi. H. Sourij received unrestricted research grants from Astra Zeneca, Boehringer Ingelheim, MSD, Novo Nordisk and Sanofi. The remaining authors have no duality of interest to disclose.